Effect of garlic powder consumption on body composition in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease that is becoming a public health problem in recent decades. Obesity and overweight play a key role in NAFLD pathogenesis. Thus, weight loss (especially body fat mass) is one component of therapeutic strategies in NAFLD. Results from experimental studies have shown that garlic (Allium sativum L.) can reduce body weight and body fat mass. However, the effect of garlic on body fat mass and weight in the human population, which is addressed in this study, is still obscure. Materials and Methods: In this clinical trial, 110 subjects with NAFLD were randomly assigned to the intervention or the control group. The intervention group received two garlic tablets (containing 400 mg of garlic powder) daily while the control group received placebo tablets. Dietary intake and physical activity of participants were obtained by a validated questionnaire. Body composition was measured by bioelectrical impedance analysis. Data were analyzed using SPSS software version 16. Results: In the intervention group, significant reductions were observed in body weight and body fat mass (P < 0.05). We also observed a significant reduction in body weight in the control group, but there were no significant changes in total body water and lean body mass in both groups (P > 0.05). In the intervention group, the percentage change in body weight was significantly greater than the control group (−2.6 vs. −0.7, P = 0.02). No serious side effects associated with the intervention were reported. Conclusion: Our trial suggests that garlic supplemfrom experimental studies have shown thatentation can reduce body weight and fat mass among subjects with NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Non-Alcoholic Fatty Liver Disease
Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G. (2010) · Digestive Diseases · doi:10.1159/000282080 · Cited by 1,026 · cited 1×
“[6] The prevalence of NAFLD in obese, diabetic, and dyslipidemic patients has been estimated to be about 80–90%, 30–50%, and 90%, respectively.[7]”
Background(1996) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/64.3.524s · Cited by 549
Weinheimer, E. M., Sands, L. P., & Campbell, W. W. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00298.x · Cited by 391
Resistance Training Conserves Fat-Free Mass and Resting Energy Expenditure Following Weight Loss
Hunter, G. R., Byrne, N. M., Sirikul, B., Fernández, J. R., Zuckerman, P. A., Darnell, B. E., & Gower, B. A. (2008) · Obesity · doi:10.1038/oby.2008.38 · Cited by 173 · cited 1×
“The weight loss is often accompanied by a loss of lean body mass, which has deleterious metabolic consequences.[26,27] Therefore, this finding demonstrated that garlic could have beneficial effects on lean body mass.”
BackgroundBariatric Surgery and Non-Alcoholic Fatty Liver Disease: Current and Potential Future Treatments
Sasaki, A., Nitta, H., Otsuka, K., Umemura, A., Baba, S., Obuchi, T., & Wakabayashi, G. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00164 · Cited by 133
Sobenin, I. A., Pryanishnikov, V. V., Kunnova, L. M., Rabinovich, Y. A., Martirosyan, D. M., & Orekhov, A. N. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-119 · Cited by 114 · cited 1×
“Current studies also suggest that consumption of garlic can reduce the risk of cardiovascular diseases.[13-15] Garlic contains many organosulfur compounds that its biological activities are attributed to them.”
BackgroundLee, M.-S., Kim, I.-H., Kim, C.-T., & Kim, Y. (2011) · The Journal of Nutrition · doi:10.3945/jn.111.146050 · Cited by 100
1,2-Vinyldithiin from garlic inhibits differentiation and inflammation of human preadipocytes
Keophiphath, M., Priem, F., Jacquemond-Collet, I., Clément, K., & Lacasa, D. (2009) · The Journal of Nutrition · doi:10.3945/jn.109.105452 · Cited by 77
Han, C. Y., Ki, S. H., Kim, Y. W., Noh, K., Lee, D. Y., Kang, B., Ryu, J.-H., Jeon, R., Kim, E. H., Hwang, S. J., et al. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3190 · Cited by 63 · cited 1×
“Evidence from cellular and animal studies suggested that garlic can exert anti-obesity properties.[16-18] However, the anti-obesity effect of garlic in the human population is still obscure.”
Background
Cited by
Potential Health Benefit of Garlic Based on Human Intervention Studies: A Brief Overview
Ansary, J., Forbes-Hernández, T. Y., Gil, E., Cianciosi, D., Zhang, J., Elexpuru-Zabaleta, M., Simal-Gandara, J., Giampieri, F., & Battino, M. (2020) · Antioxidants · doi:10.3390/antiox9070619 · Cited by 217
Therapeutic role of functional components in Alliums for preventive chronic disease in human being
Zeng, Y., Li, Y., Yang, J., Pu, X., Du, J., Yang, X., Yang, T., & Yang, S. (2017) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2017/9402849 · Cited by 157
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis
Komolafe, O., Buzzetti, E., Linden, A., Best, L. M., Madden, A. M., Roberts, D., Chase, T. J., Fritche, D., Freeman, S. C., Cooper, N. J., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013157.pub2 · Cited by 21
Metadata
- Authors
- Soleimani, D., Paknahad, Z., Askari, G., Iraj, B., & Feizi, A.
- Venue
- Advanced Biomedical Research
- Published
- 2016-01
- Volume
- 5
- Issue
- 1
- Pages
- 2-2
- ISSN
- 2277-9175 (ISSN-L)
- OpenAlex
- W2298290656
- Cited by
- 43
- References
- 9
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of garlic powder consumption on body composition in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.4103/2277-9175.174962
- The paper
- Soleimani, D., Paknahad, Z., Askari, G., Iraj, B., & Feizi, A. (2016). Effect of garlic powder consumption on body composition in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Advanced Biomedical Research. https://doi.org/10.4103/2277-9175.174962
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.